News
Bristol Myers Squibb bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nod
Overview
The FDA granted accelerated approval on Aug. 13 to Bristol Myers Squibb’s Zenbexus (iberdomide), used with Darzalex and dexamethasone, for adults with multiple myeloma who have had at least one prior line of therapy. It is the first approval in the CELMoD class — oral agents that recruit the cell’s own disposal machinery to degrade a disease-driving protein rather than simply block it. In the Phase 3 EXCALIBER-RRMM trial, 41% of patients on the Zenbexus regimen reached an MRD-negative complete response, versus 21% on the Darzalex/Velcade/dexamethasone comparator at 16 months’ median follow-up. The approval is also a regulatory first: it rests on minimal residual disease negativity as the surrogate endpoint rather than progression-free survival, following FDA draft guidance issued in January 2026. BMS’s second CELMoD, mezigdomide, carries a May 13, 2027 action date; William Blair analysts project U.S. Zenbexus sales above $1 billion by early 2031.
The Big Picture
FDA signing off on a validated surrogate endpoint in myeloma establishes that a well-supported biomarker can carry a registrational package, which compresses both the timeline and the raise a New York hematology-oncology company needs to reach a decision point.
Two follow-on effects are worth watching. First, the approval gives targeted protein degradation its commercial proof point, which strengthens the pitch for every degrader program in the state trying to raise on platform promise alone. Second, if MRD status becomes the gating measurement for approvals, high-sensitivity MRD testing shifts from research tool to trial infrastructure — a demand signal for the academic medical centers, hospital labs, and diagnostics companies concentrated in New York that would run those assays.
